Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease

Patients with chronic kidney disease (CKD) are exposed to uremic toxins and have an increased risk of cardiovascular disease. Some uremic toxins, like indoxyl sulfate, are agonists of the transcription factor aryl hydrocarbon receptor (AHR). These toxins induce a vascular procoagulant phenotype. Here we investigated AHR activation in patients with CKD and in a murine model of CKD. We performed a prospective study in 116 patients with CKD stage 3 to 5D and measured the AHR-Activating Potential of serum by bioassay.

Source: Kidney International - January 23, 2018 Category: Urology & Nephrology Authors: Laetitia Dou, St éphane Poitevin, Marion Sallée, Tawfik Addi, Bertrand Gondouin, Nathalie McKay, Michael S. Denison, Noémie Jourde-Chiche, Ariane Duval-Sabatier, Claire Cerini, Philippe Brunet, Françoise Dignat-George, Stéphane Burtey Tags: Clinical Investigation Source Type: research